Overview of clinicopathological/molecular characteristics and ALCAM expression in the MB cases examined.

Figshare2020-12-03 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Overview_of_clinicopathological_molecular_characteristics_and_ALCAM_expression_in_the_MB_cases_examined_/13328190 数据链接链接失效反馈

官方服务：

资源简介：

Overview of clinicopathological/molecular characteristics and ALCAM expression in the MB cases examined.

创建时间：

2020-12-03

Postoperative Serum Levels of sCD26 for Surveillance in Colorectal Cancer Patients

结直肠癌复发

肿瘤生物标志物

One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of tumor recurrence. We previously demonstrated decreased preoperative soluble

Figshare2016-01-15 更新50

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers. BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

乳腺癌药物反应

肿瘤生物标志物

Expression data from patient-derived xenografts of human triple-negative breast cancers Overall design: We used GeneChip Human 1.1 ST arrays to identify the genes differentially expressed in PDX with

NIAID Data Ecosystem20

Patient characteristics (including Age at diagnosis, Binet stage, Rai stage, IgVH mutation status (um indicates unmutated, m mutated), genomic aberrations such as deletion 11q, deletion 13q14, deletion 17p, trisomy 12, ZAP70 status (pos indicates ZAP70 expression > 20%, neg indicates ZAP70 expression < 20%) (n.d. indicates not done, 1 indicates variable present, 0 indicates variable not present).

慢性淋巴细胞白血病

肿瘤生物标志物

NIAID Data Ecosystem20

Artificial neural network identified a 20-gene panel with promising value in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in GBM patients

GBM胶质母细胞瘤

肿瘤生物标志物

Question: Which biomarker can effectively predict the immunotherapy response and prognostic benefits of GBM patients, and how can potential responders to immune checkpoint inhibitors (ICIs) be disc

Figshare2021-02-25 更新40

Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression on therapy with irinotecan og cetuximab – effect and biological markers.

结直肠癌靶向治疗

肿瘤生物标志物

Main objective: • Disease control as the sum of number of patients with CR, PR and SD. Primary endpoints: Disease control as sum of number of patients with CR, PR, and SD

NIAID Data Ecosystem20

Overview of clinicopathological/molecular characteristics and ALCAM expression in the MB cases examined.

资源简介：

相关数据集